Resilience acquires Ology Bioservices

By The Science Advisory Board staff writers

April 13, 2021 -- Resilience has purchased biologic drug substance manufacturing firm Ology Bioservices (Ology Bio); terms of the deal were not disclosed.

For Resilience, the deal adds 300 skilled employees, as well as over 200,000 sq ft of manufacturing, office, process development, and quality assurance/control space across locations in Florida, California, and Maryland. Additional expansion projects are also underway, according to the company.

Alachua, FL-based Ology Bio develops and manufactures drugs and biologics for commercial customers, as well as the U.S. government. It has been awarded more than $1.8 billion in government contracts, including a $37 million contract in November to develop an anti-COVID-19 monoclonal antibody cocktail, according to Resilience.

Resilience customers can utilize Ology Bio's services, including regulatory support from preclinical development through licensure, clinical trial operations support, bioanalytical testing, as well as current good manufacturing practice manufacturing up to Biosafety Level 3, the company said. Ology Bio can manufacture cell and gene therapies, live viral vaccines and vectors, oncolytic viruses, plasmids, and monoclonal antibodies.

Resilience expands U.S. biologics manufacturing footprint
Resilience is building its North American presence for biologics manufacturing through the acquisition of two commercial manufacturing facilities, one...
Inovio expands COVID-19 vaccine manufacturing with Kaneka
Inovio has brought Belgium-based Kaneka Eurogentec on board a global consortium of companies that will be manufacturing its DNA COVID-19 vaccine INO-4800,...
Inovio begins late phase clinical trials for COVID-19 vaccine
Inovio has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with the phase II segment of its phase II/III clinical trial...
Thermo Fisher to manufacture Inovio's COVID-19 vaccine
Thermo Fisher Scientific has signed a letter of intent to manufacture Inovio's DNA COVID-19 vaccine candidate, INO-4800.
DOD grant accelerates SARS-CoV-2 vaccine manufacturing
The U.S. Department of Defense (DOD) has awarded Ology Bioservices and Inovio Pharmaceuticals an $11.9 million contract to rapidly manufacture DNA...

Copyright © 2021

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter